Trials / Completed
CompletedNCT03225365
Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma
Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab. The aim of the study is to characterize the immune cells modulations under anti-PD-1 +/- anti-CTLA4 and identify the differences between responder and non-responder patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Blood and biopsy sampling | Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression. Skin biopsies will be taken at week 1, week 7, week 53 or at the progression. |
Timeline
- Start date
- 2019-10-10
- Primary completion
- 2021-06-15
- Completion
- 2021-06-15
- First posted
- 2017-07-21
- Last updated
- 2025-09-17
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03225365. Inclusion in this directory is not an endorsement.